ý
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
|
Delaware
|
20-4427682
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
4105 Hopson Road
Morrisville, North Carolina
|
27560
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
|
Name of each exchange on which registered
|
Common Stock, $0.0001 per share
|
|
The Nasdaq Global Market
|
|
|
Page
|
PART III
|
|
|
Item 10.
|
||
Item 11.
|
||
Item 12.
|
||
Item 13.
|
||
Item 14.
|
||
|
|
|
PART IV
|
|
|
Item 15.
|
||
|
|
Name of Director
|
|
Age
|
|
Principal Occupation
|
|
Director Since
|
Class I Directors:
|
|
|
|
|
|
|
John Palmour, Ph.D. (1)(3)
|
|
58
|
|
Vice President and Chief Technology Officer, Wolfspeed, a Cree, Inc. company
|
|
2010
|
Paula Brown Stafford (4)
|
|
54
|
|
President and Chief Operating Officer, Novan, Inc.
|
|
2017
|
Eugene Sun, M.D. (3)(4)
|
|
59
|
|
Senior Medical Advisor to the Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services
|
|
2018
|
|
|
|
|
|
|
|
Class II Directors:
|
|
|
|
|
|
|
Robert A. Ingram (3)
|
|
76
|
|
General Partner, Hatteras Venture Advisors III, LLC
|
|
2011
|
G. Kelly Martin
|
|
60
|
|
Chief Executive Officer, Novan, Inc.
|
|
2015
|
Machelle Sanders (2)(4)
|
|
55
|
|
Secretary of the N.C. Department of Administration
|
|
2017
|
Class III Directors:
|
|
|
|
|
|
|
W. Kent Geer (1)(2)
|
|
64
|
|
Managing Director—Finance and Investor Relations, Med1 Ventures, LLC
|
|
2015
|
Robert J. Keegan (1)(2)
|
|
71
|
|
Retired Chief Executive Officer, Goodyear Tire and Rubber Co.
|
|
2016
|
(1)
|
Member of our audit committee
|
(2)
|
Member of our compensation committee
|
(3)
|
Member of our nominating and corporate governance committee
|
(4)
|
Member of our science and technology committee
|
Name
|
|
Age
|
|
Position(s)
|
G. Kelly Martin
|
|
60
|
|
Chief Executive Officer and Director
|
Paula Brown Stafford
|
|
54
|
|
President, Chief Operating Officer and Director
|
John M. Gay
|
|
42
|
|
Vice President, Finance and Corporate Controller
|
•
|
G. Kelly Martin,
Chief Executive Officer;
|
•
|
Paula Brown Stafford,
President and
Chief Operating Officer
; and
|
•
|
Nathan Stasko, Ph.D.,
Former President and Chief Scientific Officer
|
Name and Principal Position
|
|
Fiscal Year
|
|
Salary
($)
|
|
Bonus
($)
|
|
Stock Awards
($)(1)
|
|
Option Awards
($)(2)
|
|
Non-Equity Incentive Plan Compensation
($)(3)
|
|
All Other Compensation
($)(4)
|
|
Total
($)
|
||||||||||||||||
G. Kelly Martin (5)
|
|
2018
|
|
$
|
170,909
|
|
|
|
$
|
560,000
|
|
(6)
|
|
$
|
105,534
|
|
|
$
|
593,010
|
|
|
$
|
—
|
|
|
$
|
30,522
|
|
|
$
|
1,459,975
|
|
Chief Executive Officer
|
|
2017
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
100,000
|
|
|
—
|
|
|
38,125
|
|
|
138,125
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Paula Brown Stafford (7)
|
|
2018
|
|
288,000
|
|
(8)
|
|
134,400
|
|
(9)
|
|
7,021
|
|
|
25,513
|
|
|
—
|
|
|
—
|
|
|
454,934
|
|
|||||||
President and Chief Operating Officer
|
|
2017
|
|
171,467
|
|
(8)
|
|
118,315
|
|
(9)
|
|
—
|
|
|
491,540
|
|
|
60,000
|
|
|
33,000
|
|
|
874,322
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Nathan Stasko (10)
|
|
2018
|
|
400,008
|
|
|
|
—
|
|
|
|
10,532
|
|
|
73,517
|
|
|
—
|
|
|
9,355
|
|
|
493,412
|
|
|||||||
Former President and Chief Scientific Officer
|
|
2017
|
|
393,340
|
|
|
|
—
|
|
|
|
—
|
|
|
125,635
|
|
|
235,004
|
|
|
8,730
|
|
|
762,709
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Amounts reflect the grant-date fair value of minimum bonus amounts established by our compensation committee for our named executive officers under our Tangible Stockholder Return Plan, which is a performance-based long-term incentive plan (the “Performance Plan”) that directly ties compensation to the performance of our common stock. Minimum bonus amounts under the Performance Plan are contingent and only become payable if the Company achieves the Performance Plan’s established share price targets of $11.17 and $25.45. See the section entitled “Narrative to Summary Compensation Table—Performance Plan” for a further description of the Performance Plan. Performance Plan minimum bonus award fair values are estimated using a Monte Carlo simulation approach in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 718, rather than the amounts payable to or realized by the named individual. For a discussion of the assumptions used to estimate the value of the Performance Plan awards made to our named executive officers, see Notes 1 and 11 in “Item 8. Financial Statements and Supplementary Data” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies
|
(2)
|
Amounts reflect the grant-date fair value of equity-based awards granted to our named executive officers, as applicable, including: (i) stock options in 2018 and 2017; and (ii) Stock Appreciation Rights (“SARs”) in 2018. Both stock option and SARs fair values are estimated using the Black Scholes Option Pricing Model in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. For a discussion of the assumptions used to estimate the value of the options and SARs made to our named executive officers, see Notes 1 and 10 in “Item 8. Financial Statements and Supplementary Data” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Use of Estimates—Share-Based Compensation” included in our Annual Report on Form 10-K filed with the SEC on March 27, 2019.
|
(3)
|
The Company did not award performance-based cash bonuses under the Company’s Senior Executive Annual Incentive Plan in 2018. For a description of the named executive officers’ annual bonus opportunities, please review the section entitled “Item 11. Executive Compensation—Narrative to Summary Compensation Table—Annual Bonuses.”
|
(4)
|
All other compensation includes matching contributions made under our 401(k) plan, premiums for executive life insurance, and a housing allowance for Mr. Martin. In addition, prior to Ms. Stafford’s commencement date as our Chief Development Officer, we made certain payments totaling approximately $33,000 to Habergeon LLC, where Ms. Stafford is managing director, for consulting services rendered.
|
(5)
|
Mr. Martin began serving as our Chief Executive Officer on an interim basis in June 2017, before being appointed as our Chief Executive Officer in April 2018. We did not pay Mr. Martin any compensation in 2017 for his capacity as interim Chief Executive Officer, and the 2017 amounts shown here reflect compensation paid pursuant to our non-employee director compensation policy until Mr. Martin was named as our permanent Chief Executive Officer in April 2018.
|
(6)
|
The amount disclosed as bonus represents a one-time signing bonus in August 2018 in conjunction with the execution of Mr. Martin’s employment agreement following his April 2018 appointment as our Chief Executive Officer. In determining the amount of the one-time signing bonus, our compensation committee considered the fact that Mr. Martin received no executive compensation while serving as our interim Chief Executive Officer from June 2017 through April 2018, nor did he receive executive compensation from April 2018 until his employment agreement became effective in August 2018.
|
(7)
|
Ms. Stafford began serving as our Chief Development Officer on a part-time basis effective March 20, 2017 and became our President and Chief Operating Officer on a full-time basis effective January 2, 2019.
|
(8)
|
Ms. Stafford served as our Chief Development Officer on a part-time basis in 2018 and 2017 and received base compensation at a rate of $288,000, equivalent to 75% of $384,000 on a full-time basis. Ms. Stafford became our President and Chief Operating Officer on a full-time basis effective January 2, 2019 and entered into a new employment agreement effective January 29, 2019, as described in further detail within the section entitled “Arrangements with our Named Executive Officers—Arrangements with Paula Brown Stafford.”
|
(9)
|
The amount disclosed as bonus represents bonus compensation paid to Ms. Stafford in accordance with the terms of her executed 2017 offer letter, as amended, for her service as our Chief Development Officer.
|
(10)
|
On December 31, 2018, as contemplated by Dr. Stasko’s Employment Agreement to occur following the appointment of Mr. Martin as Chief Executive Officer, upon request of our board of directors, Dr. Stasko resigned from his positions as President and director of the Company. Dr. Stasko resigned from his position as our Chief Scientific Officer effective January 4, 2019.
|
•
|
Mr. Martin received $170,909 which reflects the prorated amount of Mr. Martin’s $480,000 annual salary, for services rendered from August 8, 2018 (the effective date of his employment agreement) through December 31, 2018;
|
•
|
Ms. Stafford received $288,000 in accordance with the terms of her executed 2017 offer letter, as amended, which reflects the part-time equivalent to a full-time annual salary of $384,000; and
|
•
|
Dr. Stasko received $400,008 pursuant to his employment agreement.
|
•
|
Mr. Martin earned and received a one-time cash signing bonus of $560,000 in August 2018 in connection with the execution of his employment agreement and following Mr. Martin being named our permanent Chief Executive Officer in April 2018. In determining the amount of the one-time signing bonus, our compensation committee took into consideration the fact that Mr. Martin received no executive compensation from June 2017 through April 2018 while serving as the Chief Executive Officer on an interim basis, nor did he receive executive compensation from April 2018 until his employment agreement became effective in August 2018. Mr. Martin’s employment agreement does not provide for an annual target cash bonus opportunity under our Senior Executive Annual Incentive Plan.
|
•
|
Ms. Stafford earned cash bonuses of $134,400 during 2018 in accordance with the terms of her executed 2017 offer letter, as amended, for her service as our Chief Development Officer.
|
•
|
Dr. Stasko was eligible for a 2018 target bonus opportunity equal to 60% of his base salary, payable based on performance criteria. Dr. Stasko did not receive a bonus for 2018 due to his resignation as of January 4, 2019.
|
•
|
In August 2018, our compensation committee established that Mr. Martin will receive the following minimum bonus amounts:
|
o
|
If the Performance Plan’s first share price target of $11.17 per share is achieved, Mr. Martin will receive a minimum bonus amount under the Performance Plan of $5,250,000. If the Performance Plan’s first share price target is not achieved, no bonus award will be disbursed.
|
o
|
If the Performance Plan’s second share price target of $25.45 per share is achieved and Mr. Martin is serving as our Chief Executive Officer, he will receive a minimum bonus amount of $10,500,000 or, if the Performance Plan’s second share price target of $25.45 per share is achieved and he is serving as a director but is no longer serving as our Chief Executive Officer, he will instead receive a minimum bonus amount of $8,000,000.
|
o
|
If the Performance Plan’s second share price target is not achieved or if Mr. Martin is not serving as either CEO or a director at the time the target is achieved, no bonus award will be disbursed.
|
o
|
Mr. Martin’s minimum bonus amount under the Performance Plan is a contingent, performance-based award that, together with Mr. Martin’s SAR Award (as defined below), was implemented by our compensation committee in lieu of a stock option or other form of equity grant and targeted to be commensurate with an equity position typically granted to the chief executive officer of comparable life sciences companies.
|
•
|
In November 2018, our compensation committee established that, if the Performance Plan’s first share price target of $11.17 per share is achieved, Ms. Stafford will receive a minimum bonus amount under the Performance Plan of $500,000. If the Performance Plan’s first share price target is not achieved, no bonus award will be disbursed. In January 2019, our compensation committee established that Ms. Stafford would be entitled to an additional minimum bonus amount of $250,000, bringing her total potential minimum bonus amount upon achievement of the first share price of $11.17 per share of common stock to $750,000.
|
•
|
Also in November 2018, our compensation committee established that, if the Performance Plan’s first share price target of $11.17 per share is achieved, Dr. Stasko would receive a minimum bonus amount under the Performance Plan of $750,000. However, our compensation committee has the ability under the Performance Plan to tie receipt of awards to employment or service obligations. Following his resignation in January 2019, Dr. Stasko is no longer entitled to any bonus amount under the Performance Plan.
|
•
|
medical, dental and vision benefits;
|
•
|
medical and dependent care flexible spending accounts;
|
•
|
short-term and long-term disability insurance; and
|
•
|
life insurance.
|
|
|
Option Awards
|
|
Stock Awards
|
||||||||||||||||||
Name
|
|
Grant
Date
|
|
|
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
|
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
|
Option
Exercise
Price
($/Share)
|
|
Option
Expiration
Date
|
|
Equity Incentive Plan Awards: Number of unearned shares, units or other right that have not vested (#)
|
|
Equity Incentive Plan Awards: Payout value of unearned shares, units or other right that have not vested ($)
|
|
||||||
G. Kelly Martin
|
|
09/20/16
|
(1)
|
|
14,484
|
|
|
—
|
|
|
$
|
11.00
|
|
|
09/19/26
|
|
|
|
|
|
||
Chief Executive Officer
|
|
06/05/17
|
(2)
|
|
34,014
|
|
|
—
|
|
|
4.64
|
|
|
06/04/27
|
|
|
|
|
|
|||
|
|
08/16/18
|
(3)
|
|
1,000,000
|
|
|
—
|
|
|
3.80
|
|
|
02/01/20
|
|
|
|
|
|
|||
|
|
08/08/18
|
|
|
|
|
|
|
|
|
|
|
(4)
|
|
$
|
15,750,000
|
|
(5)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Paula Brown Stafford
|
|
03/20/17
|
(6)
|
|
54,000
|
|
|
—
|
|
|
6.53
|
|
|
03/20/27
|
|
|
|
|
|
|||
President and
Chief Operating Officer
|
|
08/25/17
|
(7)
|
|
30,500
|
|
|
—
|
|
|
4.27
|
|
|
08/14/27
|
|
|
|
|
|
|||
|
10/12/17
|
(8)
|
|
68,401
|
|
|
—
|
|
|
5.03
|
|
|
10/11/27
|
|
|
|
|
|
||||
|
|
02/12/18
|
(9)
|
|
3,711
|
|
|
8,435
|
|
|
3.03
|
|
|
02/11/28
|
|
|
|
|
|
|||
|
|
11/13/18
|
|
|
|
|
|
|
|
|
|
|
(4)
|
|
500,000
|
|
(10)
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Nathan Stasko (11)
|
|
12/29/14
|
(12)
|
|
45,000
|
|
|
—
|
|
|
1.12
|
|
|
12/28/24
|
|
|
|
|
|
|||
Former President and Chief Scientific Officer
|
|
02/29/16
|
(13)
|
|
113,333
|
|
|
6,667
|
|
|
15.20
|
|
|
02/28/26
|
|
|
|
|
|
|||
|
06/12/17
|
(14)
|
|
21,250
|
|
|
21,250
|
|
|
4.23
|
|
|
06/11/27
|
|
|
|
|
|
||||
|
|
07/06/17
|
(15)
|
|
—
|
|
|
80,000
|
|
|
3.82
|
|
|
07/05/27
|
|
|
|
|
|
|||
|
|
02/12/18
|
(16)
|
|
10,694
|
|
|
24,306
|
|
|
3.03
|
|
|
02/11/28
|
|
|
|
|
|
|||
|
|
11/13/18
|
|
|
|
|
|
|
|
|
|
|
(4)
|
|
750,000
|
|
(17)
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
The option was granted under the 2016 Plan and vests in four equal quarterly installments, with the first installment vesting on December 20, 2016.
|
(2)
|
The option was granted under the 2016 Plan and vests in four equal quarterly installments, with the first installment vesting on September 5, 2017.
|
(3)
|
The SARs were granted on a contingent basis by our board under the 2016 Plan and are subject to stockholder approval. The SARs vest will vest in full on February 1, 2020. See the section entitled “Item 11. Executive Compensation—Narrative to Summary Compensation Table—Long-term Performance-based Compensation—2016 Stock Plan” for further details regarding the SARs’ terms.
|
(4)
|
Minimum bonus amounts established by our compensation committee under the Performance Plan—the Performance Plan provides for the bonus pool to generally be paid in the form of cash, and awards are denominated in cash. Our compensation committee has discretion to pay any bonus award under the Performance Plan in the form of cash, shares of our common stock or a combination thereof, provided that our board and stockholders have approved the reservation of shares of our common stock for such payment.
|
(5)
|
The amount reflects the minimum bonus amount payable to Mr. Martin as of December 31, 2018 under the Performance Plan if the first share price target of $11.17 and second share price target of $25.45 per share is achieved. If the Performance Plan’s first share price target is not achieved, no bonus award will be disbursed under the Performance Plan. See “Item 11. Executive Compensation—Narrative to Summary Compensation Table—Long-term Performance-based Compensation—Performance Plan” for further information regarding the Performance Plan.
|
(6)
|
The option was granted under the 2016 Plan and vested six months from March 20, 2017.
|
(7)
|
The option was granted under the 2016 Plan and vested in four equal quarterly installments, with the first installment vesting on September 5, 2017.
|
(8)
|
The option was granted under the 2016 Plan and vested six months from October 12, 2017.
|
(9)
|
The option was granted under the 2016 Plan and vests in thirty-six equal monthly installments on the first day of each month following February 12, 2018.
|
(10)
|
The amount reflects the minimum bonus amount payable to Ms. Stafford as of December 31, 2018 under the Performance Plan if the first share price target of $11.17 per share is achieved. If the Performance Plan’s first share price target is not achieved, no bonus award will be disbursed. See “Item 11. Executive Compensation—Narrative to Summary Compensation Table—Long-term Performance-based Compensation—Performance Plan” for further information regarding the Performance Plan.
|
(11)
|
On December 31, 2018, as contemplated by Dr. Stasko’s Employment Agreement to occur following the appointment of Mr. Martin as Chief Executive Officer, upon request of our board of directors, Dr. Stasko resigned from his positions as President and director of the Company. Dr. Stasko resigned from his position as our Chief Scientific Officer effective January 4, 2019.
|
(12)
|
The option was granted under the Novan, Inc. 2008 Stock Plan, or the 2008 Plan, and vests in thirty-six equal monthly installments on the first day of each month following December 1, 2014. This option was forfeited and cancelled in early April 2019 following Dr. Stasko’s resignation from his position as our Chief Scientific Officer in early January 2019.
|
(13)
|
The option was granted under the 2008 Plan and vests in thirty-six equal monthly installments on the first day of each month following February 29, 2016. This option was forfeited and cancelled in early April 2019 following Dr. Stasko’s resignation from his position as our Chief Scientific Officer in early January 2019.
|
(14)
|
The option was granted under the 2016 Plan and vests in thirty-six equal monthly installments each month following June 12, 2017. This option was forfeited and cancelled in early April 2019 following Dr. Stasko’s resignation from his position as our Chief Scientific Officer in early January 2019.
|
(15)
|
The option was granted under the 2016 Plan and included vesting terms whereby the option would vest if and only if certain performance criteria were satisfied. This option was forfeited and cancelled in early April 2019 following Dr. Stasko’s resignation from his position as our Chief Scientific Officer in early January 2019.
|
(16)
|
The option was granted under the 2016 Plan and vests in thirty-six equal monthly installments each month following February 12, 2018. This option was forfeited and cancelled in early April 2019 following Dr. Stasko’s resignation from his position as our Chief Scientific Officer in early January 2019.
|
(17)
|
The amount reflects the minimum bonus amount payable to Dr. Stasko as of December 31, 2018 under the Performance Plan if the first share price target of $11.17 per share is achieved. Following his resignation in January 2019, Dr. Stasko is no longer entitled to any bonus amount under the Performance Plan.
|
Name
|
|
Fees Earned or
Paid in Cash
|
|
Option Awards (1)
|
|
Total
|
|||
W. Kent Geer
|
|
$
|
76,250
|
|
$
|
42,376
|
|
$
|
118,626
|
Robert A. Ingram
|
|
|
66,318
|
|
|
42,376
|
|
|
108,694
|
Robert J. Keegan
|
|
|
57,500
|
|
|
42,376
|
|
|
99,876
|
Sean Murphy
|
|
|
30,693
|
|
|
42,376
|
|
|
73,069
|
John Palmour
|
|
|
47,500
|
|
|
42.376
|
|
|
89,876
|
Machelle Sanders
|
|
|
46,483
|
|
|
42,376
|
|
|
88,859
|
Eugene Sun
|
|
|
49,290
|
|
|
72,503
|
|
|
121,793
|
|
(1)
|
Amounts reflect the grant-date Black-Scholes value of stock awards and stock options granted during 2018, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. For a discussion of the assumptions used to calculate the value of all stock awards and option awards made to our directors, see Notes 1 and 10 to our financial statements and the discussion under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Use of Estimates—Share-Based Compensation” included in our Annual Report on Form 10-K filed with the SEC on March 27, 2019. These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the applicable directors.
|
Name
|
|
Options Outstanding at Fiscal
Year End December 31, 2018
|
W. Kent Geer
|
|
83,748
|
Robert A. Ingram
|
|
68,498
|
Robert J. Keegan
|
|
68,498
|
John Palmour
|
|
68,498
|
Machelle Sanders
|
|
39,240
|
Eugene Sun
|
|
33,078
|
Plan Category
|
Number of Securities
to be Issued upon
Exercise of
Outstanding Options
|
|
|
Weighted Average
Exercise Price of
Outstanding Options
|
|
|
Number of Securities
Remaining Available
for Future Issuances
under Equity
Compensation Plans
(excluding securities
reflected in column (a))
|
|
|||
|
(a)
|
|
|
($)(b)
|
|
|
(c)
|
|
|||
Equity Compensation Plans approved by security holders (4)
|
1,571,166
|
(1)
|
|
$
|
5.57
|
|
(2)
|
|
699,376
|
(3)
|
|
Equity Compensation Plans not approved by security holders (5)
|
100,500
|
|
|
3.15
|
|
|
|
-
|
|
||
Total
|
1,671,666
|
|
|
|
5.42
|
|
|
|
699,376
|
|
|
(1)
|
Includes shares of common stock issuable upon exercise of outstanding options under the 2008 Plan – 243,909 shares; and the 2016 Plan – 1,327,257 shares.
|
(2)
|
The weighted-average remaining contractual term (in years) was 8.41.
|
(3)
|
Includes shares remaining for future issuance under the 2016 Plan.
|
(4)
|
During the first quarter of 2019, we issued equity compensation awards to our existing and newly hired employees, including certain of our officers, and certain equity compensation awards were forfeited or expired. As a result, as of March 31, 2019, there were 1,546,877 securities to be issued upon exercise of outstanding options, including 221,743 shares under the 2008 Plan and 1,325,134 shares under the 2016 Plan. The weighted average exercise price of outstanding options as of March 31, 2019, was
$5.30, and t
he weighted average remaining contractual term (in years) was 8.33. As of March 31, 2019, there were 701,499 shares remaining for future issuance under the 2016 Plan.
|
(5)
|
In May 2018, we awarded nonstatutory stock options to purchase an aggregate of 100,500 shares of common stock to newly-hired employees, not previously employees or directors of Novan, as inducements material to the individuals’ entering into employment with us within the meaning of Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”). The Inducement Grants have a grant date of May 31, 2018 and an exercise price of $3.15 per share. The Inducement Grants were awarded outside of the 2016 Plan, pursuant to Nasdaq Listing Rule 5635(c)(4), but have terms and conditions generally consistent with our 2016 Plan and vest over three years, with one-third of the award vesting on each annual anniversary of the employee’s employment commencement date, subject to the employee’s continued service as an employee through the vesting period. All 100,500 Inducement Grants were outstanding as of December 31, 2018.
|
•
|
each stockholder known by us to be the beneficial owner of more than 5% of our common stock;
|
•
|
each of our directors;
|
•
|
each of our named executive officers; and
|
•
|
all of our directors and executive officers as a group.
|
Number of Shares Beneficially Owned
|
|
Number of Shares
Beneficially
Owned
|
|
Percentage of
Outstanding Shares |
5% Stockholders:
|
|
|
|
|
Reedy Creek Investments LLC (1)
|
|
7,894,736
|
|
26.30%
|
Malin Life Sciences Holdings Limited (2)
|
|
2,623,485
|
|
10.06%
|
Directors and Named Executive Officers:
|
|
|
|
|
G. Kelly Martin (3)
|
|
88,498
|
|
*
|
Paula Brown Stafford (4)
|
|
158,299
|
|
*
|
Nathan Stasko (5)
|
|
823,833
|
|
3.16%
|
Robert A. Ingram (6)
|
|
183,275
|
|
*
|
W. Kent Geer (7)
|
|
89,576
|
|
*
|
Robert J. Keegan (8)
|
|
126,533
|
|
*
|
John Palmour (9)
|
|
611,941
|
|
2.34%
|
Machelle Sanders (10)
|
|
34,240
|
|
*
|
Eugene Sun (11)
|
|
28,078
|
|
*
|
All current directors and executive officers, as a group (9 persons) (12)
|
|
1,349,607
|
|
5.07%
|
*
|
Represents beneficial ownership of less than one percent.
|
(1)
|
Reedy Creek Investments LLC (“Reedy Creek”) is the direct owner of 3,947,368 shares of common stock and 3,947,368 shares of common stock issuable upon exercise of outstanding warrants. Mr. Donald R. Parker is the sole member of the board of managers and the president and chief executive officer, treasurer and chief financial officer of Reedy Creek. The James H. Goodnight Management Trust (the “Trust”) owns a majority of the equity interests in Reedy Creek and has the right to appoint a majority of the members of the board of managers of Reedy Creek. Dr. James H. Goodnight is the sole trustee of the Trust and directs the voting and investment activities of the Trust. Each of Mr. Parker, the Trust and Dr. Goodnight may be deemed to share voting and dispositive power with respect to the securities owned by Reedy Creek. As such, Mr. Parker, the Trust and Dr. Goodnight may be deemed to be the indirect beneficial owners of the securities owned by Reedy Creek. Each of Mr. Parker, the Trust and Dr. Goodnight disclaims beneficial ownership of the securities owned by Reedy Creek, except to the extent of his and, with respect to the Trust, its, pecuniary interest therein, if any. The mailing address of Reedy Creek, the Trust and each of the foregoing individuals is 100 SAS Campus Drive, Cary, NC 27513.
|
(2)
|
Malin Life Sciences Holdings Limited is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares. The mailing address of Malin Life Sciences Holdings Limited is 2 Harbour Square, Crofton Road, Dun Laoghaire, Co., Dublin, Ireland.
|
(3)
|
Consists of (i) 40,000 shares of common stock held by Mr. Martin and (ii) options to purchase 48,498 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(4)
|
Consists of options to purchase 158,299 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(5)
|
Consists of 823,833 shares of common stock held by The Stasko Living Trust, with Dr. Stasko as trustee. All of Dr. Stasko’s outstanding options to purchase common stock were forfeited on April 4, 2019, 90 days after Dr. Stasko’s resignation from his position as our Chief Scientific Officer on January 4, 2019.
|
(6)
|
Consists of (i) 119,777 shares of common stock held by Mr. Ingram and (ii) options to purchase 63,498 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(7)
|
Consists of (i) 10,828 shares of common stock held by Mr. Geer and (ii) options to purchase 78,748 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(8)
|
Consists of (i) 63,035 shares of common stock held by the Robert J. Keegan Trust, with Mr. Keegan as trustee, and (ii) options to purchase 63,498 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(9)
|
Consists of (i) 548,443 shares of common stock, of which 274,875 are held by the Palmour 2012 Irrevocable Children’s Trust, with Dr. Palmour as trustee, and (ii) options to purchase 63,498 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(10)
|
Consists of options to purchase 34,240 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(11)
|
Consists of options to purchase 28,078 shares of common stock that are exercisable within 60 days of March 31, 2019.
|
(12)
|
Consists of (i) 782,083 common shares held by our current executive officers and current directors and (ii) options and warrants to purchase 567,524 shares of common stock exercisable within 60 days of March 31, 2019.
|
|
Fiscal Year Ended
|
|||||||
|
2018
|
|
2017
|
|||||
|
(in thousands)
|
|||||||
Audit Fees (1)
|
$
|
257
|
|
|
$
|
—
|
|
|
Audit-related Fees
|
|
—
|
|
|
|
—
|
|
|
Tax Fees
|
|
—
|
|
|
|
—
|
|
|
All Other Fees
|
|
—
|
|
|
|
—
|
|
|
Total Fees
|
$
|
257
|
|
|
$
|
—
|
|
(1)
|
Audit fees consist of fees billed for professional services rendered for the audit of our consolidated annual financial statements, review of the interim consolidated financial statements, the issuance of consent and comfort letters in connection with registration statement filings with the SEC and all services that are normally provided by the accounting firm in connection with statutory and regulatory filings or engagements.
|
(a)
|
The following documents are included in this Annual Report on Form 10-K/A:
|
(3)
|
List of Exhibits.
|
|
|
|
|
|
|
INCORPORATED BY REFERENCE
|
||||||
EXHIBIT NO.
|
|
DESCRIPTION
|
|
Filed Herewith
|
|
FORM
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
3.1
|
|
|
|
|
8-K
|
|
001-37880
|
|
3.1
|
|
September 27, 2016
|
|
3.2
|
|
|
|
|
8-K
|
|
001-37880
|
|
3.2
|
|
September 27, 2016
|
|
4.1
|
|
|
|
|
8-K
|
|
001-37880
|
|
4.1
|
|
January 9, 2018
|
|
10.1
|
#
|
|
|
|
S-1
|
|
333-213276
|
|
10.1
|
|
August 24, 2016
|
|
10.2
|
#
|
|
|
|
S-1
|
|
333-213276
|
|
10.2
|
|
August 24, 2016
|
|
10.3
|
#
|
|
|
|
S-8
|
|
333-219913
|
|
99.1
|
|
August 11, 2017
|
|
10.4
|
#
|
|
|
|
10-K
|
|
001-37880
|
|
10.4
|
|
March 20, 2017
|
|
10.5
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.4
|
|
November 8, 2018
|
|
10.6
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.1
|
|
November 14, 2016
|
|
10.7
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.2
|
|
November 14, 2016
|
|
10.8
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.3
|
|
November 14, 2016
|
|
10.9
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.3
|
|
August 8, 2018
|
|
10.10
|
#
|
|
|
|
S-1
|
|
333-213276
|
|
10.4
|
|
August 24, 2016
|
|
10.11
|
#
|
|
|
|
8-K
|
|
001-37880
|
|
10.1
|
|
June 5, 2017
|
|
10.12
|
#
|
|
|
|
8-K
|
|
001-37880
|
|
10.1
|
|
January 7, 2019
|
|
|
|
|
|
|
INCORPORATED BY REFERENCE
|
||||||
EXHIBIT NO.
|
|
DESCRIPTION
|
|
Filed Herewith
|
|
FORM
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
10.13
|
#
|
|
|
|
10-K
|
|
001-37880
|
|
10.16
|
|
March 27, 2018
|
|
10.14
|
#
|
|
*
|
|
|
|
|
|
|
|
|
|
10.15
|
#
|
|
|
|
8-K
|
|
001-37880
|
|
10.1
|
|
April 17, 2018
|
|
10.16
|
#
|
|
*
|
|
|
|
|
|
|
|
|
|
10.17
|
†#
|
|
*
|
|
|
|
|
|
|
|
|
|
10.18
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.2
|
|
November 8, 2018
|
|
10.19
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.3
|
|
November 8, 2018
|
|
10.20
|
#
|
|
|
|
10-Q
|
|
001-37880
|
|
10.1
|
|
August 8, 2018
|
|
10.21
|
†
|
|
|
|
S-1/A
|
|
333-213276
|
|
10.7
|
|
September 8, 2016
|
|
10.22
|
†
|
|
|
|
10-Q
|
|
001-37880
|
|
10.4
|
|
November 14, 2016
|
|
10.23
|
†
|
|
*
|
|
|
|
|
|
|
|
|
|
10.24
|
†
|
|
|
|
S-1
|
|
333-213276
|
|
10.8
|
|
August 24, 2016
|
|
10.25
|
†
|
|
|
|
10-K
|
|
001-37880
|
|
10.21
|
|
March 27, 2018
|
|
|
|
|
|
|
INCORPORATED BY REFERENCE
|
||||||
EXHIBIT NO.
|
|
DESCRIPTION
|
|
Filed Herewith
|
|
FORM
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
10.26
|
†
|
|
*
|
|
|
|
|
|
|
|
|
|
10.27
|
†
|
|
|
|
S-1
|
|
333-213276
|
|
10.9
|
|
August 24, 2016
|
|
10.28
|
†
|
|
|
|
10-K
|
|
001-37880
|
|
10.23
|
|
March 27, 2018
|
|
10.29
|
†
|
|
*
|
|
|
|
|
|
|
|
|
|
10.30
|
†
|
|
|
|
10-K
|
|
001-37880
|
|
10.17
|
|
March 20, 2017
|
|
10.31
|
†
|
|
|
|
10-K
|
|
001-37880
|
|
10.18
|
|
March 20, 2017
|
|
10.32
|
†
|
|
|
|
10-Q
|
|
001-37880
|
|
10.1
|
|
November 5, 2018
|
|
10.33
|
|
|
|
|
S-1
|
|
333-213276
|
|
10.11
|
|
August 24, 2016
|
|
10.34
|
|
|
|
|
10-Q
|
|
001-37880
|
|
10.7
|
|
November 14, 2016
|
|
10.35
|
|
|
|
|
S-1
|
|
333-213276
|
|
10.12
|
|
August 24, 2016
|
|
23.1
|
|
|
*
|
|
|
|
|
|
|
|
|
|
23.2
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCORPORATED BY REFERENCE
|
||||||
EXHIBIT NO.
|
|
DESCRIPTION
|
|
Filed Herewith
|
|
FORM
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
31.1
|
|
|
*
|
|
|
|
|
|
|
|
|
|
31.2
|
|
|
*
|
|
|
|
|
|
|
|
|
|
31.3
|
|
|
X
|
|
|
|
|
|
|
|
|
|
31.4
|
|
|
X
|
|
|
|
|
|
|
|
|
|
32.1
|
|
|
*
|
|
|
|
|
|
|
|
|
|
32.2
|
|
|
*
|
|
|
|
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document.
|
|
*
|
|
|
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document.
|
|
*
|
|
|
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
*
|
|
|
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Document.
|
|
*
|
|
|
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
*
|
|
|
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
*
|
|
|
|
|
|
|
|
|
†
|
Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.
|
#
|
Indicates management contract or compensatory plan.
|
*
|
Indicates that the exhibit was previously filed or furnished on or with the Annual Report on Form 10-K on March 27, 2019, as applicable.
|
|
|
Novan, Inc.
|
|
|
|
|
|
Date: April 30, 2019
|
|
By:
|
/s/ G. Kelly Martin
|
|
|
|
G. Kelly Martin
|
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
1.
|
I have reviewed this annual report on Form 10-K/A of Novan, Inc. (the “registrant”); and
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|
|
By:
|
/s/ G. Kelly Martin
|
April 30, 2019
|
|
G. Kelly Martin
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
1.
|
I have reviewed this annual report on Form 10-K/A of Novan, Inc. (the “registrant”); and
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|
|
By:
|
/s/ John M. Gay
|
April 30, 2019
|
|
John M. Gay
|
|
|
Vice President, Finance and Corporate Controller
|
|
|
(Principal Financial Officer)
|